Aurobindo Pharma's board approved a buyback of up to 54.24 lakh shares (0.93% equity) at INR 1,475 per share, aggregating to INR 800 crores.
The buyback will be executed via the tender offer route, with a record date of April 17, 2026, to determine shareholder eligibility.
The buyback size represents 3.93% and 2.62% of the standalone and consolidated net worth, respectively, as per the latest audited financials.